Cargando…

Influence of PJ34 on the genotoxicity induced by melphalan in human multiple myeloma cells

INTRODUCTION: The aim of this study was to evaluate the potential biological activity of N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-(N,N-dimethylamino)acetamide hydrochloride (PJ34) on the genotoxicity induced by melphalan in human multiple myeloma cells. MATERIAL AND METHODS: The inhibitory effects of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiong, Ting, Chen, Xiaoqiong, Wei, Heng, Xiao, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2015
Materias:	Basic Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424240/ https://www.ncbi.nlm.nih.gov/pubmed/25995744 http://dx.doi.org/10.5114/aoms.2014.43164

Ejemplares similares

The Poly(Adenosine Diphosphate-Ribose) Polymerase Inhibitor PJ34 Reduces Pulmonary Ischemia-Reperfusion Injury in Rats
por: Hatachi, Go, et al.
Publicado: (2014)

Pneumocystis jirovecii (Pj) quantitative PCR to differentiate Pj pneumonia from Pj colonization in immunocompromised patients
por: Maillet, M., et al.
Publicado: (2013)

The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2022)

PJ accu (?)
Publicado: (1989)

The phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts
por: Visochek, Leonid, et al.
Publicado: (2019)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

The Modified Phenanthridine PJ34 Unveils an Exclusive Cell-Death Mechanism in Human Cancer Cells
por: Cohen-Armon, Malka
Publicado: (2020)

Correction: The phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts
por: Visochek, Leonid, et al.
Publicado: (2020)

Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: Ge, Qunfang, et al.
Publicado: (2022)

Retracted: Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
por: Srour, Samer A., et al.
Publicado: (2021)

Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma
por: Gillich, Cédric, et al.
Publicado: (2023)

The mechanism of treatment of multiple myeloma with metformin by way of metabolism
por: Song, Yanyan, et al.
Publicado: (2020)

Frataxin Deficiency Promotes Excess Microglial DNA Damage and Inflammation that Is Rescued by PJ34
por: Shen, Yan, et al.
Publicado: (2016)

Small PARP inhibitor PJ-34 induces cell cycle arrest and apoptosis of adult T-cell leukemia cells
por: Bai, Xue Tao, et al.
Publicado: (2015)

Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
por: Gourzones, Claire, et al.
Publicado: (2019)

TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan
por: Håland, Erling, et al.
Publicado: (2021)

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
por: Byun, Ja Min, et al.
Publicado: (2018)

Repeat administration of high dose melphalan in relapsed myeloma.
por: Mansi, J. L., et al.
Publicado: (1993)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Functional analysis of the involvement of apurinic/apyrimidinic endonuclease 1 in the resistance to melphalan in multiple myeloma
por: Xie, Jiayin, et al.
Publicado: (2014)

Comparison of two melphalan protocols and evaluation of outcome and prognostic factors in multiple myeloma in dogs
por: Fernández, Ricardo, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma
por: Cao, Yaohua, et al.
Publicado: (2021)

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)

A case report: high dose melphalan as a conditioning regimen for multiple myeloma induces sinus arrest
por: Ma, Liang-Liang, et al.
Publicado: (2020)

763 The Cardioprotective Effects of Sildenafil, PJ34, MitoTEMPO, and ZLN005 in the Early After Burn Injury
por: Radhakrishnan, Ravi, et al.
Publicado: (2023)

4530 Elucidating the Influence of Chemotherapy (melphalan) and /or C. difficile toxin B Exposure on Beta-catenin Protein Expression in Caco-2 Monolayers
por: Canales, Jailene, et al.
Publicado: (2020)

A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients.
por: Belch, A., et al.
Publicado: (1988)

Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies—Current Research and Clinical Approaches
por: Poczta, Anastazja, et al.
Publicado: (2021)

Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma
por: Morabito, Fortunato, et al.
Publicado: (2021)

Cytotoxic efficacy of filanesib and melphalan combination is governed by sequence of treatment in human myeloma cells
por: Norris, E J, et al.
Publicado: (2016)

Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Reduces Brain Damage after Stroke in the Neonatal Mouse Brain
por: Bonnin, Philippe, et al.
Publicado: (2021)

Effect of melphalan and hyperthermia on p34cdc2 kinase activity in human melanoma cells.
por: Orlandi, L., et al.
Publicado: (1996)

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
por: Azarm, Taleb, et al.
Publicado: (2012)

Comparable Outcomes using Propylene Glycol-Free Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2018)

Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105)
por: Maruyama, Dai, et al.
Publicado: (2020)

Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma
por: Nath, Christa Ellen, et al.
Publicado: (2022)

The Impact of Renal Impairment in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation With Melphalan Conditioning
por: Ursu, Sorana G., et al.
Publicado: (2023)

Factors influencing the chemosensitization of melphalan by misonidazole.
por: Randhawa, V. S., et al.
Publicado: (1985)

Cannot write session to /tmp/vufind_sessions/sess_s7fi9jlj5dc9hl0spkko0fller